InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,760.45
(
-0.21%
)
Post# of 251715
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

TwoNE1

Send PM Follow Ignore
Followers 1
Posts 129
Boards Moderated 0
Alias Born 01/27/2011

TwoNE1

Re: TwoNE1 post# 244621

Friday, 05/12/2023 8:11:13 AM

Friday, May 12, 2023 8:11:13 AM

Post# of 251715
$SPRY / $AQST: FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

https://finance.yahoo.com/news/fda-advisory-committee-votes-support-230100445.html

$AQST
Aquestive will most likely benefit from this decision as it will simplify the eventual approval of their product (sublingual epinephrine film).
https://www.healio.com/news/allergy-asthma/20230315/sublingual-epinephrine-film-beats-syringes-autoinjectors-in-time-to-maximum-concentration
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up